Physician profile
Divya Asti
NPI 1821475138
$9,215.39
in general payments reported to CMS, 2019-2025
53 companies · $3,674 in 2025
The $3,674 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2022: $177 · 2023: $1,102 · 2024: $4,163 · 2025: $3,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,738 · Long Term Medical Supply Or Device Loan: $2,164 · Education: $38.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,737.51 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Education | $38.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,876.20 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $570.21 | 2023-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $541.86 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Gilead Sciences, INC. | $427.28 | 2023-2025 | Trodelvy |
| Incyte Corporation | $365.04 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $352.72 | 2024-2025 | Tecvayli, Rybrevant, Akeega |
| Merck Sharp & Dohme LLC | $346.93 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $343.23 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $331.10 | 2023-2025 | |
| Daiichi Sankyo INC. | $283.04 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Pfizer INC. | $178.72 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.25 | 2024-2025 | Ninlaro, Iclusig, Vpriv |
| Lilly USA, LLC | $155.25 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $153.17 | 2023-2025 | Libtayo |
| Stryker Corporation | $146.20 | 2025 | Mako |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $141.59 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Glaxosmithkline, LLC. | $141.33 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Pharmaceuticals, INC | $136.25 | 2024 | Xarelto |
| Amgen INC. | $120.77 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Bayer Healthcare Pharmaceuticals INC. | $112.54 | 2024-2025 | |
| Eisai INC. | $111.17 | 2024-2025 | |
| Stemline Therapeutics INC. | $104.66 | 2023-2025 | Orserdu |
| Abbvie INC. | $92.13 | 2024-2025 | |
| Genmab U.S., INC. | $71.89 | 2024 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $67.55 | 2024-2025 | Onivyde, Somatuline Depot |
| Karyopharm Therapeutics INC. | $60.25 | 2023 | Xpovio |
| Astellas Pharma US INC | $59.15 | 2024-2025 | Vyloy, Xospata |
| Puma Biotechnology, INC. | $57.86 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $57.83 | 2024-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $56.69 | 2024 | Qinlock, Tgct |
| Myriad Genetic Laboratories, INC. | $46.96 | 2024 | Precisetumor |
| Servier Pharmaceuticals LLC | $43.05 | 2024-2025 | |
| Geron Corporation | $40.33 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $35.47 | 2024-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $33.38 | 2023 | Krazati |
| Blueprint Medicines Corporation | $29.56 | 2024-2025 | Ayvakit |
| Pharmaessentia USA Corporation | $29.18 | 2025 | Besremi |
| Morphosys, US INC. | $24.74 | 2024 | Monjuvi |
| Array Biopharma INC | $24.59 | 2025 | Lorbrena, Braftovi, Xalkori |
| Cti Biopharma Corp. | $24.22 | 2022 | |
| Tactile Systems Technology INC | $21.89 | 2023 | Entre Plus, Flexitouch Plus |
| Sun Pharmaceutical Industries INC. | $21.61 | 2025 | |
| Sirtex Medical INC | $21.41 | 2024 | Sir-Spheres Microspheres |
| Tersera Therapeutics LLC | $20.87 | 2024 | Zoladex |
| Spectrum Pharmaceuticals INC. | $20.82 | 2024 | Rolvedon |
| Taiho Oncology, INC. | $20.59 | 2025 | |
| Sobi, INC | $19.97 | 2025 | |
| Aveo Pharmaceuticals, INC. | $19.43 | 2025 | |
| Adc Therapeutics America, INC. | $18.97 | 2023 | |
| Emd Serono, INC. | $18.58 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.31 | 2025 | |
| Legend Biotech USA INC. | $18.13 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $13.47 | 2025 | Rezlidhia, Tavalisse, Gavreto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Asti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.